Evidence map›Paper›PMID 40837487›Full record

ArticleData in brief2025

Draft genome sequencing and

Madina Alexyuk, Andrey Bogoyavlenskiy, Kuralay Akanova, Yergali Moldakhanov, Adolat Manakbayeva, Timur Kerimov, Vladimir Berezin, Pavel Alexyuk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Madina AlexyukResearch and Production Center for Microbiology and Virology, 050010, Bogenbay batyr. Str., 105, Almaty, Kazakhstan.
Andrey BogoyavlenskiyResearch and Production Center for Microbiology and Virology, 050010, Bogenbay batyr. Str., 105, Almaty, Kazakhstan.
Kuralay AkanovaResearch and Production Center for Microbiology and Virology, 050010, Bogenbay batyr. Str., 105, Almaty, Kazakhstan.
Yergali MoldakhanovResearch and Production Center for Microbiology and Virology, 050010, Bogenbay batyr. Str., 105, Almaty, Kazakhstan.
Adolat ManakbayevaResearch and Production Center for Microbiology and Virology, 050010, Bogenbay batyr. Str., 105, Almaty, Kazakhstan.
Timur KerimovResearch and Production Center for Microbiology and Virology, 050010, Bogenbay batyr. Str., 105, Almaty, Kazakhstan.
Vladimir BerezinResearch and Production Center for Microbiology and Virology, 050010, Bogenbay batyr. Str., 105, Almaty, Kazakhstan.
Pavel AlexyukResearch and Production Center for Microbiology and Virology, 050010, Bogenbay batyr. Str., 105, Almaty, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the significant challenges of modern public health is the global spread of drug resistance among bacterial pathogens. According to WHO forecasts mortality from resistant bacterial infections by 2050 may reach up to 10 million cases per year. One of the ways to solve this problem is the mass introduction of phage therapy into medical practice, which requires the search, isolation, and study of lytic bacteriophages that can effectively fight resistant bacterial infections. In this study, we report on the genome of the lytic vB_EcoM_AMO3598 bacteriophage isolated from wastewater in Almaty city, targeting clinical, antibiotic-resistant

Indexed as

Antibiotic resistanceBacteriophageEscherichia coliGenome annotationIllumina sequencing

Identifiers

PMID40837487
PMCPMC12363465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.